Federal Medicare Hemp Program Advances Through CMS Review Process

CMS Finalizes Comment Period on Hemp Coverage Rule

The Centers for Medicare & Medicaid Services closed the public comment window on its hemp-derived cannabinoid coverage rule on May 26, 2026, moving the proposal into final rule drafting. The agency received more than 14,000 comments during the 60-day window that opened in March. CMS Administrator Chiquita Brooks-LaSure said in a statement that the agency will publish a final rule by October 2026. Implementation is targeted for January 1, 2027.

The proposed rule applies exclusively to hemp-derived products that have completed FDA approval under the drug development pathway. It doesn't extend to over-the-counter CBD products or state-legal cannabis medicines.

Scope Limited to FDA-Approved Hemp Drugs

Medicare Part D plans would cover only hemp-derived cannabinoid drugs that hold FDA approval as prescription medications. Currently, no such products exist on the market. Epidiolex, the FDA-approved CBD drug for epilepsy, is derived from cannabis and remains a Schedule III controlled substance, excluding it from this rule's scope.

The distinction matters. Hemp is defined under the 2018 Farm Bill as cannabis containing no more than 0.3 percent THC by dry weight, and products meeting that threshold while securing FDA approval would qualify for Medicare reimbursement under the proposed framework.

Industry Stakeholders Split on Impact

Cannabis industry trade groups have offered mixed reactions. Some view the rule as a potential onramp for broader federal acceptance. Others dismiss it as irrelevant to state-legal markets. The U.S. Hemp Roundtable praised CMS for recognizing hemp's therapeutic potential. Aaron Smith, co-founder of the National Cannabis Industry Association, said the rule underscores the federal government's inconsistent treatment of cannabis and hemp, given that most state-legal cannabis products remain federally prohibited.

The proposal creates a two-tier system where hemp companies can access Medicare dollars while cannabis operators face 280E tax penalties and banking restrictions.

No Immediate Beneficiary Access

Zero products currently qualify for coverage. The rule establishes a framework, not a formulary. Pharmaceutical companies developing hemp-derived drugs would need to complete Phase III trials, secure FDA approval, and negotiate pricing with Part D plan sponsors before any beneficiary could fill a prescription.

That timeline likely extends beyond 2028 for the first covered product, according to regulatory analysts at Cowen Washington Research Group.

State-Legal Cannabis Remains Excluded

The rule doesn't change Medicare's prohibition on covering state-legal cannabis products, even those recommended by physicians in medical marijuana programs. Cannabis remains a Schedule I controlled substance under the Controlled Substances Act, barring federal insurance reimbursement regardless of state law. The Drug Enforcement Administration's ongoing rescheduling review, which would move cannabis to Schedule III, wouldn't alter this exclusion because Medicare Part D covers only FDA-approved drugs.

Political and Regulatory Context

CMS published the proposed rule under authority granted by the 2018 Farm Bill, which removed hemp from the Controlled Substances Act. The agency acted without new congressional authorization, relying on existing Medicare Part D statutory language that allows coverage of any FDA-approved outpatient prescription drug not otherwise excluded.

Republican and Democratic committee leaders in the House Energy and Commerce Committee haven't commented publicly on the rule. The Senate Finance Committee, which oversees Medicare policy, held no hearings on the proposal.

What Comes Next

CMS will review public comments and issue a final rule by October 2026. Stakeholders are watching whether the agency narrows or expands the definition of eligible hemp-derived products and whether it establishes any coverage limitations or prior authorization requirements. For comprehensive background on this policy development, see the CannIntel topic hub on the Medicare Hemp Program. Implementation depends on pharmaceutical companies bringing FDA-approved hemp drugs to market, a process that remains years away for most candidates in the development pipeline.